Single vs. combination immunotherapeutic strategies for glioma

Autores
Chandran, Mayuri; Candolfi, Marianela; Shah, Diana; Mineharu, Yohei; Yadav, Viveka Nand; Koschmann, Carl; Asad, Antonela Sofía; Lowenstein, Pedro R.; Castro, Maria Gabriela
Año de publicación
2017
Idioma
inglés
Tipo de recurso
artículo
Estado
versión publicada
Descripción
Introduction: Malignant gliomas are highly invasive tumors, associated with a dismal survival rate despite standard of care, which includes surgical resection, radiotherapy and chemotherapy with temozolomide (TMZ). Precision immunotherapies or combinations of immunotherapies that target unique tumor-specific features may substantially improve upon existing treatments. Areas covered: Clinical trials of single immunotherapies have shown therapeutic potential in high-grade glioma patients, and emerging preclinical studies indicate that combinations of immunotherapies may be more effective than monotherapies. In this review, the authors discuss emerging combinations of immunotherapies and compare efficacy of single vs. combined therapies tested in preclinical brain tumor models. Expert opinion: Malignant gliomas are characterized by a number of factors which may limit the success of single immunotherapies including inter-tumor and intra-tumor heterogeneity, intrinsic resistance to traditional therapies, immunosuppression, and immune selection for tumor cells with low antigenicity. Combination of therapies which target multiple aspects of tumor physiology are likely to be more effective than single therapies. While a limited number of combination immunotherapies are described which are currently being tested in preclinical and clinical studies, the field is expanding at an astounding rate, and endless combinations remain open for exploration.
Fil: Chandran, Mayuri. University of Michigan; Estados Unidos
Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Shah, Diana. University of Michigan; Estados Unidos
Fil: Mineharu, Yohei. Kyoto University; Japón
Fil: Yadav, Viveka Nand. University of Michigan; Estados Unidos
Fil: Koschmann, Carl. University of Michigan; Estados Unidos
Fil: Asad, Antonela Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos
Fil: Castro, Maria Gabriela. University of Michigan; Estados Unidos
Materia
Cancer Vaccines
Gene Therapy
Glioma
Immune Checkpoint Blockade
Immunotherapy
Nivel de accesibilidad
acceso abierto
Condiciones de uso
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
Repositorio
CONICET Digital (CONICET)
Institución
Consejo Nacional de Investigaciones Científicas y Técnicas
OAI Identificador
oai:ri.conicet.gov.ar:11336/66841
Acceder
id CONICETDig_23648bae7dea2519d68eecfdf4a4a291
oai_identifier_str oai:ri.conicet.gov.ar:11336/66841
network_acronym_str CONICETDig
repository_id_str 3498
network_name_str CONICET Digital (CONICET)
spelling Single vs. combination immunotherapeutic strategies for gliomaChandran, MayuriCandolfi, MarianelaShah, DianaMineharu, YoheiYadav, Viveka NandKoschmann, CarlAsad, Antonela SofíaLowenstein, Pedro R.Castro, Maria GabrielaCancer VaccinesGene TherapyGliomaImmune Checkpoint BlockadeImmunotherapyhttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3Introduction: Malignant gliomas are highly invasive tumors, associated with a dismal survival rate despite standard of care, which includes surgical resection, radiotherapy and chemotherapy with temozolomide (TMZ). Precision immunotherapies or combinations of immunotherapies that target unique tumor-specific features may substantially improve upon existing treatments. Areas covered: Clinical trials of single immunotherapies have shown therapeutic potential in high-grade glioma patients, and emerging preclinical studies indicate that combinations of immunotherapies may be more effective than monotherapies. In this review, the authors discuss emerging combinations of immunotherapies and compare efficacy of single vs. combined therapies tested in preclinical brain tumor models. Expert opinion: Malignant gliomas are characterized by a number of factors which may limit the success of single immunotherapies including inter-tumor and intra-tumor heterogeneity, intrinsic resistance to traditional therapies, immunosuppression, and immune selection for tumor cells with low antigenicity. Combination of therapies which target multiple aspects of tumor physiology are likely to be more effective than single therapies. While a limited number of combination immunotherapies are described which are currently being tested in preclinical and clinical studies, the field is expanding at an astounding rate, and endless combinations remain open for exploration.Fil: Chandran, Mayuri. University of Michigan; Estados UnidosFil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; ArgentinaFil: Shah, Diana. University of Michigan; Estados UnidosFil: Mineharu, Yohei. Kyoto University; JapónFil: Yadav, Viveka Nand. University of Michigan; Estados UnidosFil: Koschmann, Carl. University of Michigan; Estados UnidosFil: Asad, Antonela Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; ArgentinaFil: Lowenstein, Pedro R.. University of Michigan; Estados UnidosFil: Castro, Maria Gabriela. University of Michigan; Estados UnidosInforma Healthcare2017-05info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/resource_type/c_6501info:ar-repo/semantics/articuloapplication/pdfapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/66841Chandran, Mayuri; Candolfi, Marianela; Shah, Diana; Mineharu, Yohei; Yadav, Viveka Nand; et al.; Single vs. combination immunotherapeutic strategies for glioma; Informa Healthcare; Expert Opinion on Biological Therapy; 17; 5; 5-2017; 543-5541471-25981744-7682CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451096/info:eu-repo/semantics/altIdentifier/doi/10.1080/14712598.2017.1305353info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/14712598.2017.1305353info:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-nd/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-10-15T15:21:04Zoai:ri.conicet.gov.ar:11336/66841instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-10-15 15:21:04.268CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse
dc.title.none.fl_str_mv Single vs. combination immunotherapeutic strategies for glioma
title Single vs. combination immunotherapeutic strategies for glioma
spellingShingle Single vs. combination immunotherapeutic strategies for glioma
Chandran, Mayuri
Cancer Vaccines
Gene Therapy
Glioma
Immune Checkpoint Blockade
Immunotherapy
title_short Single vs. combination immunotherapeutic strategies for glioma
title_full Single vs. combination immunotherapeutic strategies for glioma
title_fullStr Single vs. combination immunotherapeutic strategies for glioma
title_full_unstemmed Single vs. combination immunotherapeutic strategies for glioma
title_sort Single vs. combination immunotherapeutic strategies for glioma
dc.creator.none.fl_str_mv Chandran, Mayuri
Candolfi, Marianela
Shah, Diana
Mineharu, Yohei
Yadav, Viveka Nand
Koschmann, Carl
Asad, Antonela Sofía
Lowenstein, Pedro R.
Castro, Maria Gabriela
author Chandran, Mayuri
author_facet Chandran, Mayuri
Candolfi, Marianela
Shah, Diana
Mineharu, Yohei
Yadav, Viveka Nand
Koschmann, Carl
Asad, Antonela Sofía
Lowenstein, Pedro R.
Castro, Maria Gabriela
author_role author
author2 Candolfi, Marianela
Shah, Diana
Mineharu, Yohei
Yadav, Viveka Nand
Koschmann, Carl
Asad, Antonela Sofía
Lowenstein, Pedro R.
Castro, Maria Gabriela
author2_role author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Cancer Vaccines
Gene Therapy
Glioma
Immune Checkpoint Blockade
Immunotherapy
topic Cancer Vaccines
Gene Therapy
Glioma
Immune Checkpoint Blockade
Immunotherapy
purl_subject.fl_str_mv https://purl.org/becyt/ford/3.1
https://purl.org/becyt/ford/3
dc.description.none.fl_txt_mv Introduction: Malignant gliomas are highly invasive tumors, associated with a dismal survival rate despite standard of care, which includes surgical resection, radiotherapy and chemotherapy with temozolomide (TMZ). Precision immunotherapies or combinations of immunotherapies that target unique tumor-specific features may substantially improve upon existing treatments. Areas covered: Clinical trials of single immunotherapies have shown therapeutic potential in high-grade glioma patients, and emerging preclinical studies indicate that combinations of immunotherapies may be more effective than monotherapies. In this review, the authors discuss emerging combinations of immunotherapies and compare efficacy of single vs. combined therapies tested in preclinical brain tumor models. Expert opinion: Malignant gliomas are characterized by a number of factors which may limit the success of single immunotherapies including inter-tumor and intra-tumor heterogeneity, intrinsic resistance to traditional therapies, immunosuppression, and immune selection for tumor cells with low antigenicity. Combination of therapies which target multiple aspects of tumor physiology are likely to be more effective than single therapies. While a limited number of combination immunotherapies are described which are currently being tested in preclinical and clinical studies, the field is expanding at an astounding rate, and endless combinations remain open for exploration.
Fil: Chandran, Mayuri. University of Michigan; Estados Unidos
Fil: Candolfi, Marianela. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Shah, Diana. University of Michigan; Estados Unidos
Fil: Mineharu, Yohei. Kyoto University; Japón
Fil: Yadav, Viveka Nand. University of Michigan; Estados Unidos
Fil: Koschmann, Carl. University of Michigan; Estados Unidos
Fil: Asad, Antonela Sofía. Consejo Nacional de Investigaciones Científicas y Técnicas. Oficina de Coordinación Administrativa Houssay. Instituto de Investigaciones Biomédicas. Universidad de Buenos Aires. Facultad de Medicina. Instituto de Investigaciones Biomédicas; Argentina
Fil: Lowenstein, Pedro R.. University of Michigan; Estados Unidos
Fil: Castro, Maria Gabriela. University of Michigan; Estados Unidos
description Introduction: Malignant gliomas are highly invasive tumors, associated with a dismal survival rate despite standard of care, which includes surgical resection, radiotherapy and chemotherapy with temozolomide (TMZ). Precision immunotherapies or combinations of immunotherapies that target unique tumor-specific features may substantially improve upon existing treatments. Areas covered: Clinical trials of single immunotherapies have shown therapeutic potential in high-grade glioma patients, and emerging preclinical studies indicate that combinations of immunotherapies may be more effective than monotherapies. In this review, the authors discuss emerging combinations of immunotherapies and compare efficacy of single vs. combined therapies tested in preclinical brain tumor models. Expert opinion: Malignant gliomas are characterized by a number of factors which may limit the success of single immunotherapies including inter-tumor and intra-tumor heterogeneity, intrinsic resistance to traditional therapies, immunosuppression, and immune selection for tumor cells with low antigenicity. Combination of therapies which target multiple aspects of tumor physiology are likely to be more effective than single therapies. While a limited number of combination immunotherapies are described which are currently being tested in preclinical and clinical studies, the field is expanding at an astounding rate, and endless combinations remain open for exploration.
publishDate 2017
dc.date.none.fl_str_mv 2017-05
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
http://purl.org/coar/resource_type/c_6501
info:ar-repo/semantics/articulo
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv http://hdl.handle.net/11336/66841
Chandran, Mayuri; Candolfi, Marianela; Shah, Diana; Mineharu, Yohei; Yadav, Viveka Nand; et al.; Single vs. combination immunotherapeutic strategies for glioma; Informa Healthcare; Expert Opinion on Biological Therapy; 17; 5; 5-2017; 543-554
1471-2598
1744-7682
CONICET Digital
CONICET
url http://hdl.handle.net/11336/66841
identifier_str_mv Chandran, Mayuri; Candolfi, Marianela; Shah, Diana; Mineharu, Yohei; Yadav, Viveka Nand; et al.; Single vs. combination immunotherapeutic strategies for glioma; Informa Healthcare; Expert Opinion on Biological Therapy; 17; 5; 5-2017; 543-554
1471-2598
1744-7682
CONICET Digital
CONICET
dc.language.none.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv info:eu-repo/semantics/altIdentifier/url/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5451096/
info:eu-repo/semantics/altIdentifier/doi/10.1080/14712598.2017.1305353
info:eu-repo/semantics/altIdentifier/url/https://www.tandfonline.com/doi/full/10.1080/14712598.2017.1305353
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
eu_rights_str_mv openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by-nc-nd/2.5/ar/
dc.format.none.fl_str_mv application/pdf
application/pdf
application/pdf
application/pdf
dc.publisher.none.fl_str_mv Informa Healthcare
publisher.none.fl_str_mv Informa Healthcare
dc.source.none.fl_str_mv reponame:CONICET Digital (CONICET)
instname:Consejo Nacional de Investigaciones Científicas y Técnicas
reponame_str CONICET Digital (CONICET)
collection CONICET Digital (CONICET)
instname_str Consejo Nacional de Investigaciones Científicas y Técnicas
repository.name.fl_str_mv CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas
repository.mail.fl_str_mv dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar
_version_ 1846083359078350848
score 13.22299

Publicaciones similares